[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2004004798A3 - Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques - Google Patents

Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques Download PDF

Info

Publication number
WO2004004798A3
WO2004004798A3 PCT/US2003/014428 US0314428W WO2004004798A3 WO 2004004798 A3 WO2004004798 A3 WO 2004004798A3 US 0314428 W US0314428 W US 0314428W WO 2004004798 A3 WO2004004798 A3 WO 2004004798A3
Authority
WO
WIPO (PCT)
Prior art keywords
systemic delivery
therapeutics
methods
products
central airway
Prior art date
Application number
PCT/US2003/014428
Other languages
English (en)
Other versions
WO2004004798A2 (fr
Inventor
Richard S Blumberg
Wayne I Lencer
Neil E Simister
Alan J Bitonti
Original Assignee
Brigham & Womens Hospital
Univ Brandeis
Childrens Medical Center
Syntonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/021335 external-priority patent/WO2003077834A2/fr
Application filed by Brigham & Womens Hospital, Univ Brandeis, Childrens Medical Center, Syntonix Pharmaceuticals Inc filed Critical Brigham & Womens Hospital
Priority to JP2004519544A priority Critical patent/JP2006513139A/ja
Priority to EP03762973A priority patent/EP1539246A4/fr
Priority to AU2003232081A priority patent/AU2003232081B2/en
Priority to CA002491129A priority patent/CA2491129A1/fr
Publication of WO2004004798A2 publication Critical patent/WO2004004798A2/fr
Publication of WO2004004798A3 publication Critical patent/WO2004004798A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des procédés et des produits destinés à l'administration systémique transépithéliale d'agents thérapeutiques. Plus particulièrement, la présente invention concerne des procédés et des compositions permettant l'administration systémique d'agents thérapeutiques par introduction d'un aérosol contenant des anticorps ou des conjugués d'un agent thérapeutique avec un partenaire de liaison FcRn dans l'épithélium des voies aériennes centrales du poumon. Les procédés et les dispositifs décrits dans cette invention peuvent s'adapter à une large gamme d'agents thérapeutiques parmi lesquels les protéines et les polypeptides, les acides nucléiques, les médicaments, etc. Ces procédés et ces produits présentent l'avantage de ne pas nécessiter d'introduction en profondeur dans le poumon pour permettre l'administration systémique.
PCT/US2003/014428 2002-07-03 2003-05-09 Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques WO2004004798A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2004519544A JP2006513139A (ja) 2002-07-03 2003-05-09 治療薬の全身性送達のための中央部気道投与
EP03762973A EP1539246A4 (fr) 2002-07-03 2003-05-09 Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques
AU2003232081A AU2003232081B2 (en) 2002-07-03 2003-05-09 Central airway administration for systemic delivery of therapeutics
CA002491129A CA2491129A1 (fr) 2002-07-03 2003-05-09 Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US02/21335 2002-07-03
PCT/US2002/021335 WO2003077834A2 (fr) 2002-03-15 2002-07-03 Apport par les voies aeriennes centrales pour l'administration systemique de medicaments

Publications (2)

Publication Number Publication Date
WO2004004798A2 WO2004004798A2 (fr) 2004-01-15
WO2004004798A3 true WO2004004798A3 (fr) 2004-10-14

Family

ID=30113575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/014428 WO2004004798A2 (fr) 2002-07-03 2003-05-09 Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques

Country Status (5)

Country Link
EP (1) EP1539246A4 (fr)
JP (1) JP2006513139A (fr)
AU (1) AU2003232081B2 (fr)
CA (1) CA2491129A1 (fr)
WO (1) WO2004004798A2 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US8039592B2 (en) 2002-09-27 2011-10-18 Xencor, Inc. Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8124731B2 (en) 2002-03-01 2012-02-28 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8318907B2 (en) 2004-11-12 2012-11-27 Xencor, Inc. Fc variants with altered binding to FcRn
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US8524867B2 (en) 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8937158B2 (en) 2003-03-03 2015-01-20 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
US9040041B2 (en) 2005-10-03 2015-05-26 Xencor, Inc. Modified FC molecules
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US9475881B2 (en) 2010-01-19 2016-10-25 Xencor, Inc. Antibody variants with enhanced complement activity

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
BRPI0507174A (pt) * 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
US8435517B2 (en) 2008-09-17 2013-05-07 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
PL2471813T3 (pl) 2004-07-15 2015-09-30 Xencor Inc Zoptymalizowane warianty Fc
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
EP3392273A1 (fr) 2007-05-30 2018-10-24 Xencor, Inc. Procédés et compositions pour inhiber des cellules exprimant cd32b
EP2173380A4 (fr) * 2007-07-13 2011-08-31 Abbott Biotech Ltd Compositions et methodes d'administration pulmonaire d'un inhibiteur du tnfa
WO2009012600A1 (fr) 2007-07-26 2009-01-29 Novagen Holding Corporation Protéines de fusion
JP5314033B2 (ja) * 2007-10-22 2013-10-16 メルク セローノ ソシエテ アノニム 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
TW200938221A (en) * 2007-11-30 2009-09-16 Abbott Lab Protein formulations and methods of making same
CN105418762B (zh) 2007-12-26 2019-11-05 Xencor公司 与FcRn结合改变的Fc变体
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
CN102492039B (zh) * 2011-11-21 2015-03-11 无锡天演生物技术有限公司 全人源抗人her2单抗
EP3495387B1 (fr) 2012-07-13 2021-09-01 Roche Glycart AG Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le traitement des maladies vasculaires oculaires
CA2897987A1 (fr) 2013-01-15 2014-07-24 Xencor, Inc. Elimination rapide de complexes antigeniques a l'aide de nouveaux anticorps
WO2015150510A1 (fr) 2014-04-03 2015-10-08 Csl Behring Ag Nébulisation d'immunoglobuline
EP3194449A1 (fr) 2014-07-24 2017-07-26 Xencor, Inc. Élimination rapide de complexes antigéniques à l'aide de nouveaux anticorps
CA2965759C (fr) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Polypeptides en poudre presentant moins d'impuretes de disulfide comprenant des materiaux cationiques divalents
EP3377622A4 (fr) * 2015-11-16 2019-06-19 The Trustees Of The University Of Pennsylvania Libération ciblée dans des types de cellules d'intérêt de protéines thérapeutiques bioencapsulées dans des cellules végétales pour le traitement de maladies
ES2963807T3 (es) 2016-06-08 2024-04-02 Xencor Inc Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B
EP4392455A2 (fr) * 2021-08-25 2024-07-03 iBio, Inc. Anticorps anti-cd-25

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US20030235536A1 (en) * 2002-03-15 2003-12-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
EP1658772A3 (fr) * 1995-01-17 2007-01-17 The Brigham And Women's Hospital, Inc. Transport épithélial spécifique de récepteurs d'immunogènes
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
WO2001059142A1 (fr) * 2000-02-09 2001-08-16 Medimmune, Inc. Therapie genique a anticorps avec vecteurs viraux adeno-associes
WO2001074397A1 (fr) * 2000-03-31 2001-10-11 Kirin Beer Kabushiki Kaisha Preparation en poudre destinee a etre administree par les muqueuses comprenant un medicament de forme polymere et presentant une stabilite de conservation amelioree
CA2430039C (fr) * 2000-11-28 2014-01-28 Medimmune, Inc. Procedes d'administration / de dosage d'anticorps anti-rsv destines a la prevention et au traitement
SE0102067D0 (sv) * 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US20030235536A1 (en) * 2002-03-15 2003-12-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1539246A4 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US8734791B2 (en) 2002-03-01 2014-05-27 Xencor, Inc. Optimized fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8124731B2 (en) 2002-03-01 2012-02-28 Xencor, Inc. Optimized Fc variants and methods for their generation
US8858937B2 (en) 2002-09-27 2014-10-14 Xencor, Inc. Optimized Fc variants and methods for their generation
US8093359B2 (en) 2002-09-27 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US8039592B2 (en) 2002-09-27 2011-10-18 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US9193798B2 (en) 2002-09-27 2015-11-24 Xencor, Inc. Optimized Fc variants and methods for their generation
US8383109B2 (en) 2002-09-27 2013-02-26 Xencor, Inc. Optimized Fc variants and methods for their generation
US8809503B2 (en) 2002-09-27 2014-08-19 Xencor, Inc. Optimized Fc variants and methods for their generation
US9353187B2 (en) 2002-09-27 2016-05-31 Xencor, Inc. Optimized FC variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8937158B2 (en) 2003-03-03 2015-01-20 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
US8735545B2 (en) 2003-03-03 2014-05-27 Xencor, Inc. Fc variants having increased affinity for fcyrllc
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US8883973B2 (en) 2004-11-12 2014-11-11 Xencor, Inc. Fc variants with altered binding to FcRn
US8318907B2 (en) 2004-11-12 2012-11-27 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8338574B2 (en) 2004-11-12 2012-12-25 Xencor, Inc. FC variants with altered binding to FCRN
US8324351B2 (en) 2004-11-12 2012-12-04 Xencor, Inc. Fc variants with altered binding to FcRn
US9040041B2 (en) 2005-10-03 2015-05-26 Xencor, Inc. Modified FC molecules
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
US9574006B2 (en) 2005-10-06 2017-02-21 Xencor, Inc. Optimized anti-CD30 antibodies
US8524867B2 (en) 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US9475881B2 (en) 2010-01-19 2016-10-25 Xencor, Inc. Antibody variants with enhanced complement activity

Also Published As

Publication number Publication date
JP2006513139A (ja) 2006-04-20
EP1539246A4 (fr) 2007-05-16
EP1539246A2 (fr) 2005-06-15
CA2491129A1 (fr) 2004-01-15
WO2004004798A2 (fr) 2004-01-15
AU2003232081A1 (en) 2004-01-23
AU2003232081B2 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
WO2004004798A3 (fr) Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques
WO2003077834A3 (fr) Apport par les voies aeriennes centrales pour l'administration systemique de medicaments
WO2005021579A3 (fr) Peptides mimetiques epo et proteines de fusion
TNSN03116A1 (en) Pulmonary administration of chemically modified insulin
WO2004019872A3 (fr) Delivrance orale de proteines hybrides modifiees de la transferrine
DE69833492D1 (en) Rezeptorspezifischer transepithelialtransport von therapuetica
WO2004082628A3 (fr) Biodisponibilite amelioree et administration amelioree de medicaments acides pharmaceutiques
WO2004041153A3 (fr) Composition pharmaceutique comprenant de faibles dosages de desmopressine
WO2004020405A3 (fr) Proteines de fusion de transferrine modifiees
BRPI0407648A (pt) uso de uma proteìna ligante sìtio-especìfica ativa juntamente com um vetor terapêutico codificando uma proteìna para manufatura de um medicamente
WO2004084950A3 (fr) Procedes et compositions de ciblage cellulaire
WO2002098390A3 (fr) Administration d'aerosols contenant de petites particules via une voie d'inhalation
WO2002032893A3 (fr) Nouveaux composes non imidazole
CA2818990C (fr) Proteines de repetition concues se liant a l'albumine serique
WO2006062723A3 (fr) Immunotherapie genique associe a une chimiotherapie pour le traitement du cancer et d'affections hyperproliferantes
WO2006020580A3 (fr) Variants de polypeptides synthetiques hyperglycosyles resistants a la protease, formulations orales et leurs procedes d'utilisation
ID29181A (id) Kombinasi formoterol dan garam tiotropium
EP1536828A4 (fr) Methodes de distribution de proteines exogenes au cytosol et leurs utilisations
WO2004041247A3 (fr) Vehicules pour administration de geodats
WO2003002152A3 (fr) Formulations d'interféron
WO2002004421A3 (fr) Analogues de pyridoxine et de pyridoxal utilises comme agents de therapie cardio-vasculaire
DE60031504D1 (de) Fluticasonpropionat arzneizubereitung
WO2003040398A3 (fr) Proteines stabilisees avec des gommes glucidiques
WO2002055098A3 (fr) Methode pour conferer un temps de latence a des substances pharmaceutiquement actives
MX2007003907A (es) Agentes terapeuticos con toxicidad reducida.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2491129

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003232081

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004519544

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003762973

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003762973

Country of ref document: EP